PCSK9 and atherosclerosis: The implementation of an M2B program for early initiation of guideline-recommended PCSK9i mAbs in patients undergoing myocardial or peripheral artery revascularization was associated with enhanced testing and attainment of LDL-C and non–HDL-C goals in a real-world clinical practice cohort.PerspectivesCOMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: Implementation of a M2B program for early initiation of PCSK9 inhibitors in hospitalized patients with ASCVD undergoing revascularization supports timely adoption of guideline-recommended therapies.